Abstract
Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival of patients and the promise of a return to normal lives. The cost of progress comes with a price, however, and the nervous system is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxic attack is directed against the peripheral nerve, targeting the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures, resulting in chemotherapy-induced peripheral neuropathy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Gastaut JL, Pellisier JF: Cisplatin-induced neuropathy. A clinical, neurophysiological and pathological study. Rev Neurol (Paris) 1985, 141:614–621.
Krarup-Hansen A, Helweg-Larsen S, et al.: Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007, 130:1076–1088.
Asbury AK: Sensory neuronopathy. Sem Neurol 1987, 7:58–66.
Cata JP, Weng HR, Lee BN, et al.: Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anesthesiol 2006, 72:151–169.
Pratt RW, Weimer LH: Medication and toxin-induced peripheral neuropathy. Sem Neurol 2005, 25:204–216.
Chaudhry V, Chaudhry M, Crawford TO, et al.: Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337–340.
Graf WD, Chance PF, Lensch MW, et al.: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996, 77:1356–1362.
Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9–17.
Stillman M, Cata JP: Management of chemotherapy-induced peripheral neuropathy Curr Pain Headache Rep 2006, 10:279–287.
Cavaletti G, Bogliun G, Marzorati L, et al.: Grading of chemotherapy induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003, 61:1297–1300.
Postma TJ, Heimans JJ: Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000, 11:509–513.
Markman M: Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists. Curr Oncol Rep 2005, 7:159–160.
Markman M: Can we do a better job preventing clinically relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy? Cancer Invest 2004, 22:471–473.
Balmaceda C, Korkin E: Cancer and cancer treatment-related neuromuscular disease. In Cancer Neurology in Clinical Practice. Edited by Schiff D, Wen PY. Totowa, NJ: Humana Press; 2003:193–213.
Postma TJ, Heimans JJ, Muller MJ: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 7:39–44.
Cavaletti G, Jann S, Pace A, et al.: Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Sys 2006, 11:135–141.
Dougherty PM, Cata JP, Cordella JV, et al.: Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 104:132–142
Forsyth PA, Balmaceda C, Peterson K, et al.: Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-oncol 1997, 35:47–53.
Argyriou AA, Polychronopoulos P, Koutros A, et al.: Peripheral neuropathy induced by administration of cisplatin-and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 2005, 13:647–651.
McCarthy BG, Hsieh ST, Stocks A, et al.: Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995, 45:1848–1855.
Hermann DN, Griffin JW, Hauer P, et al.: Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 1999, 53:1634–1640.
Plotkin SR, Wen PY: Neurological complication of cancer therapy. Neurol Clin North Am 2003, 21:279–318.
Van den Bent MJ: Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. Clin Cancer Res 2005, 11:1691–1693.
Lipton RB, Apfel SC, Dutcher JP, et al.: Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39:368–373.
Hilkens PH, Pronk LC, Verwiej J, et al.: Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997, 75:417–422.
Mielke S, Sparreboom A, Steinberg SM, et al.: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005, 11:4843–4850.
New PZ, Jackson CE, Rinaldi D, et al.: Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996, 46:108–111.
Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099–2106.
Pignata S, Biamonte R, Scambia G, et al.: Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study, BMC Cancer 2006, 6:202.
Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387–392.
Krishnan AV, Goldstein D, Friedlander M, et al.: Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51–60.
Chaudhry V, Eisenberger MA, Sinibaldi VJ, et al.: A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039–2052.
Chaudhry V, Cornblath DR, Corse A, et al.: Thalidomideinduced neuropathy. Neurology 2002, 59:1872–1875.
Openshaw H, Beamon K, Synold TW, et al.: Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004, 10:461–467.
Davis ID, Kiers L, MacGregor L, et al.: A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1890–1898.
Wen PY: A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1685–1686.
Van Gerven JM, Hovestadt A, Mall JW, et al.: The effects of an ACTH(4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 1994, 241:432–435.
Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061.
Argyriou AA, Chroni E, Koutras A, et al.: Vitamin E for prophylaxis against chemotherapy-induced neuropathy; a randomized controlled trial. Neurology 2005, 64:26–31.
Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003, 21:927–931.
Flatters SJ, Xiao WH, Bennett GJ: Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006, 397:219–223.
Bianchi G, Vitali G, Caraceni A, Ravaglia S: Symptomatic and neurophysiological responses of paclitaxel-or cisplatininduced neuropathy or oral acetyl-l-carnitine. Eur J Cancer 2005, 41:1746–1750.
Stubblefield MD, Vahdat LT, Balmaceda CM, et al.: Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiological study. Clin Oncol 2005, 17:271–276.
Cascinu S, Catalano V, Cordella L, et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478–3483.
Bianchi R, Brines M, Lauria G, et al.: Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006, 12:2607–2612.
Dworkin R, Backonja M, Rowbotham M, et al.: Advances in neuropathic pain. Arch Neurol 2003, 60:1524–1534.
Stillman M: The clinical approach to the patient with neuropathic pain. Cleve Clin J Med 2006, 73:726–743.
Durand JP, Alexandre J, Guillevin L, Goldwasser F: Clinical activity of venlafaxine and topiramate against oxaliplatininduced disabling permanent neuropathy. Anti-Cancer Drugs 2005, 16:587–591.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malik, B., Stillman, M. Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 8, 56–65 (2008). https://doi.org/10.1007/s11910-008-0010-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-008-0010-5